1/14
02:21 pm
tsha
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects [Yahoo! Finance]
Low
Report
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects [Yahoo! Finance]
1/6
03:01 pm
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
Low
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
1/6
02:33 pm
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Low
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
1/6
08:00 am
tsha
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
Medium
Report
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
1/5
08:42 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
1/3
01:08 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) was downgraded by analysts at
Wall S
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) was downgraded by analysts at
Wall S
12/22
09:30 am
tsha
Is FDA Breakthrough Status For TSHA-102 Reshaping The Investment Case For Taysha Gene Therapies (TSHA)? [Yahoo! Finance]
Medium
Report
Is FDA Breakthrough Status For TSHA-102 Reshaping The Investment Case For Taysha Gene Therapies (TSHA)? [Yahoo! Finance]
12/22
08:36 am
tsha
Taysha Gene Therapies (TSHA): Revisiting Valuation After Breakthrough Rett Data and Bullish Analyst Upgrades [Yahoo! Finance]
Medium
Report
Taysha Gene Therapies (TSHA): Revisiting Valuation After Breakthrough Rett Data and Bullish Analyst Upgrades [Yahoo! Finance]
12/21
07:42 am
tsha
Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program [Yahoo! Finance]
Medium
Report
Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program [Yahoo! Finance]
12/13
01:10 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by analysts at
Wall Str
Low
Report
Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by analysts at
Wall Str
12/5
04:05 pm
tsha
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/4
08:10 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) was given a new $11.00 price target on by analysts at UBS Group AG.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) was given a new $11.00 price target on by analysts at UBS Group AG.
12/4
07:04 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "buy" rating.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "buy" rating.
12/4
07:03 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) was given a new $11.00 price target on by analysts at The Goldman Sachs Group, Inc..
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) was given a new $11.00 price target on by analysts at The Goldman Sachs Group, Inc..
12/2
03:46 pm
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
02:19 pm
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
06:38 am
tsha
Is Taysha Gene Therapies Inc. (TSHA) One of the Must-Buy Penny Stocks to Buy Now? [Yahoo! Finance]
Low
Report
Is Taysha Gene Therapies Inc. (TSHA) One of the Must-Buy Penny Stocks to Buy Now? [Yahoo! Finance]
11/14
09:14 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
11/7
09:50 pm
tsha
Citizens Lifts Price Target for Taysha Gene Therapies (TSHA) [Yahoo! Finance]
Medium
Report
Citizens Lifts Price Target for Taysha Gene Therapies (TSHA) [Yahoo! Finance]
11/5
08:44 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) was given a new $8.00 price target on by analysts at JMP Securities.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) was given a new $8.00 price target on by analysts at JMP Securities.
11/5
08:07 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
11/5
08:07 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its price target raised by analysts at Citizens Jmp from $6.00 to $8.00. They now have a "market outperform" rating on the stock.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its price target raised by analysts at Citizens Jmp from $6.00 to $8.00. They now have a "market outperform" rating on the stock.
11/5
07:19 am
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
11/4
07:00 am
tsha
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Low
Report
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/30
12:31 pm
tsha
Taysha Gene Therapies (NASDAQ:TSHA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Taysha Gene Therapies (NASDAQ:TSHA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.